

ACURA PHARMACEUTICALS, INC  
 Form 4  
 January 06, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 ROSS GEORGE K

2. Issuer Name and Ticker or Trading Symbol  
 ACURA PHARMACEUTICALS, INC [ACUR]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 01/02/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O ACURA PHARAMCEUTICALS, INC., 616 N NORTH COURT

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

PALATINE, IL 60067

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (A) or (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	01/02/2015		M <sup>(1)</sup>	11,030 A <u>(2)</u>	14,030 <sup>(3)</sup>	D	
Common Stock	01/02/2015		F <sup>(4)</sup>	246 D 0.45 <sup>(5)</sup>	13,784 <sup>(3)</sup>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control**

SEC 1474 (9-02)

number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
					(A)	(D)	Date Exercisable	Expiration Date		
Restricted Stock Units	(2)	01/02/2015		M		11,030	(6)	(6)	Common Stock	11,030
Restricted Stock Units	(2)	01/02/2015		D		7,352	(6)	(6)	Common Stock	7,352
Restricted Stock Units	(2)	01/02/2015		A	51,546		(9)	(9)	Common Stock	51,546

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director    10% Owner    Officer    Other

ROSS GEORGE K  
C/O ACURA PHARMACEUTICALS, INC.  
616 N NORTH COURT  
PALATINE, IL 60067

X

## Signatures

/s/ George Ross                      01/06/2015

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Represents exchange of Restricted Stock Units.
- (2) Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for cash or stock
- (3) Does not include Restricted Stock Units.
- (4) For payment of par value of \$.01 per share.
- (5) Represents closing price of Issuer's common stock on December 31, 2014.

## Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 4

50% of Restricted Stock Units vested on June 30, 2014; 25% vested on September 30, 2014 and 25% vested on December 31, 2014.

Restricted Stock Units are exchanged for cash or stock on January 2, 2015, absent an election by Reporting Person. Reporting Person

- (6) elected to defer distributions with respect to 50% (18,382) of Restricted Stock Units so that they are paid in three equal installments on January 1 of 2016, 2017 and 2018. Reporting Person elected to exchange 40% (7,352) of remaining Restricted Stock Units for cash (less par value of \$.01 per share) and 60% of remaining Restricted Stock Units (11,030) on a one for one basis for common stock, in each case upon payment of, or deduction of par value.

- (7) N/A

- (8) Does not include par value of \$.01 that must be paid or deducted upon exchange for cash.

25% of Restricted Stock Units vest on the last day of each of March, June, September and December 2015. Reporting Person may elect to

- (9) exchange up to 40% of Restricted Stock Units for cash and the remaining Restricted Stock Units will be exchanged on a one for one basis for common stock, in each case upon payment of, or deduction of par value. Distributions in respect of vested Restricted Stock Units will be made on the first business day of January 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.